Eli Lilly is building a $3.5bn retatrutide factory. Why will patients wait until 2031?
Eli Lilly begins construction of its $3.5bn Pennsylvania obesity drug plant. See how retatrutide and manufacturing demand shape the investment.
Pharma & Biotech